在2005年至2015年期间,瑞典对喘进行药理治疗
Caroline Ahlroth Pind1,2, Björn Ställberg3, Karin Lisspers3
1Centre for Clinical Research, Uppsala University, Västmanland County Hospital, Västerås, Sweden.
概括
喘治疗趋势显示,吸入性皮质类固醇 (ICS) 与长效β-激动剂 (LABA) 的使用增加,但持续过度使用短效β-激动剂 (SABA). 这凸显了尽管治疗进展,但在最佳喘管理方面仍存在持续的挑战.
科学领域:
- 肺部医学 肺部医学
- 临床药房 临床药房
- 流行病学 流行病学
背景情况:
- 许多喘患者经历疾病控制不良,尽管有治疗方法.
- 吸入性皮质类固醇 (ICS) 的使用不足和短效β-激动剂 (SABA) 的过度使用是导致喘控制不足的潜在因素.
- 了解喘治疗的纵向趋势对于改善患者的治疗结果至关重要.
研究的目的:
- 调查2005年至2015年期间瑞典喘治疗模式的纵向趋势.
- 确定与特定喘治疗选择和坚持相关的因素.
- 评估十年来ICS,LABA和SABA的使用变化.
主要方法:
- 在2005年 (n=1182) 和2015年 (n=1225) 调查了两个不同的成年喘患者队列.
- 通过问卷收集有关症状,维护和救援药物使用的数据.
- 使用统计分析,包括后勤回归来检查治疗和患者特征之间的关联.
主要成果:
- 使用ICS加长效β-激动剂 (LABA) 和/或蒙特卢卡斯特的维持疗法显著增加,从39.2%增加到44.2%.
- 根据需要使用ICS+LABA增加,而SABA使用减少,尽管定期使用ICS保持稳定.
- 2015年每日SABA使用量为22.7%,与年龄,肥胖,吸烟和恶化史等因素相关.
结论:
- 随着时间的推移,ICS+LABA的使用在维护和缓解症状方面都在增加.
- 尽管有这些积极的趋势,但ICS的持续使用不足和SABA的过度使用仍然是喘管理的重大挑战.
- 需要进一步的干预措施来解决这些治疗缺口,并优化喘控制.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
455
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
455
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
310
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
310
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324